Selective Vulnerability in Striosomes and in the Nigrostriatal Dopaminergic Pathway After Methamphetamine Administration
Open Access
- 4 September 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurotoxicity Research
- Vol. 18 (1), 48-58
- https://doi.org/10.1007/s12640-009-9106-1
Abstract
Methamphetamine (METH), a commonly abused psychostimulant, causes dopamine neurotoxicity in humans, rodents, and nonhuman primates. This study examined the selective neuroanatomical pattern of dopaminergic neurotoxicity induced by METH in the mouse striatum. We examined the effect of METH on tyrosine hydroxylase (TH) and dopamine transporter (DAT) immunoreactivity in the different compartments of the striatum and in the nucleus accumbens. The levels of dopamine and its metabolites, 3,4-dihidroxyphenylacetic acid and homovanillic acid, as well as serotonin (5-HT) and its metabolite, 5-hydroxyindolacetic acid, were also quantified in the striatum. Mice were given three injections of METH (4 mg/kg, i.p.) at 3 h intervals and sacrificed 7 days later. This repeated METH injection induced a hyperthermic response and a decrease in striatal concentrations of dopamine and its metabolites without affecting 5-HT concentrations. In addition, the drug caused a reduction in TH- and DAT-immunoreactivity when compared to saline-treated animals. Interestingly, there was a significantly greater loss of TH- and DAT-immunoreactivity in striosomes than in the matrix. The predominant loss of dopaminergic terminals in the striosomes occurred along the rostrocaudal axis of the striatum. In contrast, METH did not decrease TH- or DAT-immunoreactivity in the nucleus accumbens. These results provide the first evidence that compartments of the mouse striatum, striosomes and matrix, and mesolimbic and nigrostriatal pathways have different vulnerability to METH. This pattern is similar to that observed with other neurotoxins such as MPTP, the most widely used model of Parkinson’s disease, in early Huntington’s disease and hypoxic/ischemic injury, suggesting that these conditions might share mechanisms of neurotoxicity.Keywords
This publication has 67 references indexed in Scilit:
- Methamphetamine toxicity and messengers of deathBrain Research Reviews, 2009
- Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Methamphetamine Preconditioning: Differential Protective Effects on Monoaminergic Systems in the Rat BrainNeurotoxicity Research, 2009
- effect of methamphetamine neurotoxicity on learning-inducedarc mRNA expression in identified striatal efferent neuronsNeurotoxicity Research, 2008
- Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystoniaProceedings of the National Academy of Sciences of the United States of America, 2008
- Mutual enhancement of central neurotoxicity induced by ketamine followed by methamphetamineToxicology and Applied Pharmacology, 2008
- In 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Primates, the Selective 5-Hydroxytryptamine 1a Agonist (R)-(+)-8-OHDPAT Inhibits Levodopa-Induced Dyskinesia but Only with\ Increased Motor DisabilityThe Journal of pharmacology and experimental therapeutics, 2006
- Relative Resistance of Striatal Neurons Containing Calbindin or Parvalbumin to Quinolinic Acid-Mediated Excitotoxicity Compared to Other Striatal Neuron TypesExperimental Neurology, 1998
- Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regionsJournal of Neural Transmission, 1993
- Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonistNeuropharmacology, 1992